Log in
NASDAQ:RMTI

Rockwell Medical Stock Forecast, Price & News

$0.96
-0.03 (-3.03 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.94
Now: $0.96
$1.00
50-Day Range
$0.99
MA: $1.15
$1.68
52-Week Range
$0.94
Now: $0.96
$3.85
Volume1.27 million shs
Average Volume3.40 million shs
Market Capitalization$67.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.25
Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. It is also developing an intravenous formulation of Triferic for use by hemodialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1994 and is based in Wixom, Michigan.
Read More
Rockwell Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:RMTI
CUSIP77437410
Phone248-960-9009
Employees299

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$61.30 million
Book Value$0.32 per share

Profitability

Net Income$-34,130,000.00

Miscellaneous

Market Cap$67.49 million
Next Earnings Date11/9/2020 (Estimated)
OptionableOptionable
$0.96
-0.03 (-3.03 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RMTI News and Ratings via Email

Sign-up to receive the latest news and ratings for RMTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rockwell Medical (NASDAQ:RMTI) Frequently Asked Questions

How has Rockwell Medical's stock price been impacted by COVID-19 (Coronavirus)?

Rockwell Medical's stock was trading at $2.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RMTI shares have decreased by 66.7% and is now trading at $0.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Rockwell Medical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rockwell Medical
.

When is Rockwell Medical's next earnings date?

Rockwell Medical is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Rockwell Medical
.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) released its earnings results on Monday, August, 10th. The company reported ($0.10) EPS for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.04. The company had revenue of $15.90 million for the quarter, compared to the consensus estimate of $15.80 million. Rockwell Medical had a negative return on equity of 146.49% and a negative net margin of 47.94%.
View Rockwell Medical's earnings history
.

What price target have analysts set for RMTI?

2 Wall Street analysts have issued 12 month target prices for Rockwell Medical's shares. Their forecasts range from $6.00 to $9.00. On average, they expect Rockwell Medical's stock price to reach $7.50 in the next year. This suggests a possible upside of 681.3% from the stock's current price.
View analysts' price targets for Rockwell Medical
.

Are investors shorting Rockwell Medical?

Rockwell Medical saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 4,220,000 shares, a decline of 34.5% from the September 15th total of 6,440,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is presently 2.4 days. Approximately 6.8% of the shares of the stock are sold short.
View Rockwell Medical's Short Interest
.

Who are some of Rockwell Medical's key competitors?

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seattle Genetics (SGEN), Geron (GERN), Opko Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Who are Rockwell Medical's key executives?

Rockwell Medical's management team includes the following people:
  • Dr. Ajay Gupta, Chief Scientific Officer & Member of Scientific Advisory Board (Age 62, Pay $570.68k)
  • Dr. Russell H. Ellison M.Sc., M.D., MSc., Pres, CEO & Director (Age 72)
  • Mr. Russell L. Skibsted M.B.A., Exec. VP, CFO & Chief Bus. Officer (Age 61)
  • Mr. Michael DeYoung, VP of Operations
  • Mr. Paul E. McGarry, VP, Corp. Controller & Principal Accounting Officer (Age 52)

What is Rockwell Medical's stock symbol?

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

Who are Rockwell Medical's major shareholders?

Rockwell Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Jag Capital Management LLC (0.07%). Company insiders that own Rockwell Medical stock include Angus W Smith, David S Richmond, Russell H Ellison and Stuart M Paul.
View institutional ownership trends for Rockwell Medical
.

Which major investors are buying Rockwell Medical stock?

RMTI stock was purchased by a variety of institutional investors in the last quarter, including Jag Capital Management LLC. Company insiders that have bought Rockwell Medical stock in the last two years include Angus W Smith, David S Richmond, Russell H Ellison, and Stuart M Paul.
View insider buying and selling activity for Rockwell Medical
.

How do I buy shares of Rockwell Medical?

Shares of RMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rockwell Medical's stock price today?

One share of RMTI stock can currently be purchased for approximately $0.96.

How big of a company is Rockwell Medical?

Rockwell Medical has a market capitalization of $67.49 million and generates $61.30 million in revenue each year. The company earns $-34,130,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Rockwell Medical employs 299 workers across the globe.

What is Rockwell Medical's official website?

The official website for Rockwell Medical is www.rockwellmed.com.

How can I contact Rockwell Medical?

Rockwell Medical's mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The company can be reached via phone at 248-960-9009 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.